Grifols launches new AMBAR study for Alzheimer’s treatment

Grifols has announced the launch of a new study into methods of treatment for Alzheimer's disease.

Known as the AMBAR (Alzheimer Management By Amyloid Removal) study, it will investigate combined treatment using albumin plasmapheresis and intravenous immunoglobulin (IVIG) at different doses.

The researchers will attempt to find synergies between the two treatments in order to reduce the frequency and volume of plasmapheresis, ultimately making the treatment experience more pleasant for patients and easier for medical professionals to administer.

AMBAR is expected to last two years and will be directed by Dr Merce Boada, clinical head of the neurology service at the Vall d'Hebron Hospital in Barcelona.

Dr Boada said the study "opens up new prospects and hopes in dealing with an illness where success involves maintaining the quality of life of these patients".

Alzheimer's is the most common form of dementia. It affects ten percent of all people over the age of 65 and up to 25 percent of those older than 85, according to the Alzheimer's Association.